EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
Compliance to Competitive Advantage in Pharma Supply
Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser
Advisory Board
KNOWLEDGE BANK
-
Articles
Considerations and Functional Elements of Closed Systems: Isolators and Single Use Systems
Advances in technology have demonstrated the feasibility of using isolators and singleuse systems SUS in routine pharmaceutical manufacturing operations particularly in aseptic processing Their implementation has significantly reduced the risk of chemical particulate and microbiological contamination
Market Access Strategies for Pharma Products in Europe: A Comprehensive Guide
The European pharmaceutical market is dynamic and diverse presenting both opportunities and challenges for companies seeking market access This guide delves into effective strategies for navigating the complexities of market access in Europe focusing on key aspects such as reimbursement pricing and overcoming market entry challenges
Building Resilient Pharma Supply Chains to Strengthen Patient Care
The failure to deliver a temperaturesensitive biologic or a critical maintenance drug on time is becoming a patient outcome crisis not just an operational inefficiency By fortifying our global logistics networks we proactively safeguard the availability of lifesaving therapies and essential healthcare supplies securing the healthcare industrys central promise to global health This strategic impera...
Implementing Quality by Design (QbD) in Pharmaceutical Development: Enhancing Product Quality and Regulatory Compliance
Quality by Design QbD stands as a systematic strategy for pharmaceutical development prioritizing predefined product objectives and emphasizing a thorough understanding of both the product and its manufacturing processes This proactive approach integrates quality seamlessly into the development process championing a sciencedriven
Ritonavir: How the Discovery of a New Polymorph Changed Drug Development Forever
AIDS is a chronic illness that gained global attention in the s It weakens the immune system of the body making it hard to fight infections When HIV enters the body it targets CD Tcells a type of white blood cell that helps defend against diseases It uses the machinery of Tcells to make new copies of the virus due to which the immune cells are destroyed As the virus spreads and the number of healt...
COVID-19 Vaccines & SARS-CoV-2 Variants: Who is winning the Race?
It was not uncommon to name the year as annus horribilis as the SARSCoV quickly spread all over the globe causing the first pandemic in years leading to devastating consequences on health economy and the society in general Neither drugs nor vaccines were available for more or less the whole first year of the pandemic causing devastation helplessness and uncertainty Since the beginning of the COV...
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG
PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
Market Access Strategies for Pharma Products in Europe: A Comprehensive Guide
Kate Williamson
This comprehensive guide provides pharmaceutical companies with strategic insights for navigating the diverse European market. Focusing on reimbursement, pricing, and market entry challenges, it empha...
-
2
Building Resilient Pharma Supply Chains to Strengthen Patient Care
Lesley Barton
In the complex, global ecosystem of pharmaceutical manufacturing and distribution, the supply chain is no longer merely a logistical function but a direct extension of clinical efficacy. For C-level e...
-
3
Implementing Quality by Design (QbD) in Pharmaceutical Development: Enhancing Product Quality and Regulatory Compliance
Kate Williamson
This article explores the implementation of Quality by Design (QbD) in pharmaceutical development, emphasizing its principles and practical applications. QbD ensures consistent product quality, reduce...
-
4
Ritonavir: How the Discovery of a New Polymorph Changed Drug Development Forever
Victor M. Diaz Perez
The ritonavir crisis, triggered by the unexpected discovery of a new, less soluble polymorph, reshaped the pharmaceutical industry's approach to solid state characterization. This article explores...
-
5
COVID-19 Vaccines & SARS-CoV-2 Variants: Who is winning the Race?
Kenneth Lundstrom
Although COVID-19 vaccines have proven efficient and safe, the continuous emergence of novel SARS-CoV-2 mutants, properly called variants of concern, has resulted in a race between vaccine efficacy an...
press releases Read more...
Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development
Fortrea a leading global contract research organization CRO and Omico Australias leading precision oncology screening and trial matching organization today announced a collaboration to accelerate precision oncology research by helping connect cancer patients to biomarkermatched clinical trials By co...
ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
AstraZeneca today announced the US availability of ZEGFROVY sunvozertinib for the treatment of adults with locally advanced or metastatic nonsmall cell lung cancer NSCLC whose tumors have epidermal growth factor receptor EGFR exon insertion mutations as detected by an FDAapproved test
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
Cardiff Oncology Inc a clinicalstage biotechnology company leveraging PLK inhibition to develop novel cancer therapies today announced that the US Food and Drug Administration FDA has granted Orphan Drug Designation to onvansertib for the treatment of patients with chronic myelomonocytic leukemia
Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer
Geneos Therapeutics a clinical stage biotherapeutics company focused on the development of neoantigenbased personalized immunotherapy for cancer PIC today announced the initiation of its Phase randomized clinical trial NCT in patients with highrisk hepatocellular carcinoma HCC liver cancer
Events Read more...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026Pharma Manufacturing & Automation Convention 2026
Novotel Hyderabad Airport, Ind...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
LATEST NEWS Read more...
Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent
The Menarini Group a leading international pharmaceutical and diagnostics company and Stemline Therapeutics Inc Stemline a whollyowned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients along with Georgiamune Inc a clinicalstage biotechnology...
LGM Pharma Acquires Sannova Analytical, Expanding cGMP Analytical and GLP Bioanalytical Services
LGM Pharma a leading provider of tailored API sourcing contract analytical testing and drug development services today announced it has acquired Sannova Analytical a contract research laboratory headquartered in Somerset NJ The acquisition expands LGM Pharmas analytical testing services business by...
AI Proteins Announces Research Collaboration and License Agreement With Astellas Pharma to Discover and Develop Novel Miniprotein-Based Therapeutics Valued at Over $400 Million
AI Proteins Inc a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins today announced it has entered into a Research Collaboration and License Agreement with Astellas Innovation Management LLC an affiliate of Astellas Pharma Inc TSE to discove...
Okomera Announces Trade Agreement with Servier to Use Tumor Miniaturization Technology in Cancer Research
Okomera a TechBio company that personalizes cancer management with its technology combining minivatars tumor microfluidics and AI imaging today announced the signing of a commercial agreement with Servier an independent international pharmaceutical group
ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics
ScionxBio a privately held preclinicalstage biotechnology company pioneering nextgeneration mRNA therapeutics distinguished by their extended durability profile today announced that it has entered into a worldwide strategic collaboration and licensing agreement with Sanofi
Takara Bio USA Partners with SPT Labtech to Deliver Automation-Ready NGS Library Preparation Technologies
Takara Bio USA Inc a wholly owned subsidiary of Takara Bio Inc and SPT Labtech today announced their partnership to deliver validated automated library preparation workflows that combine Takara Bio nextgeneration sequencing NGS library preparation chemistries with SPT Labtechs firefly liquid handlin...





